Glaukos stock slips after insider selling (GKOS:NYSE)

· seekingalpha.com

Glaukos Corporation (GKOS) stock drops after an insider sale overshadowed positives from a late-stage trial for the company's Epioxa eye therapy. Read more here.

Despite announcing positive data from a late-stage trial for its Epioxa eye therapy, Glaukos Corporation (GKOS) lost more than 13% on Thursday amid an insider s...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI